Cellectar Biosciences, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- James V. Caruso
- Full Time Employees
- 11
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 100 Campus Drive Florham Park NJ United States of America 07932
- IPO Date
- Nov 10, 2005
- CIK
- 0001279704
- Website
- cellectar.com
- Similar Companies
- Business
- Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary drugs for the treatment of cancer. The company leverages its proprietary phospholipid ether drug conjugate (PDC) delivery platform to develop targeted cancer therapies designed to improve efficacy and safety by selectively delivering therapeutic molecules to cancer cells while minimizing off-target effects. Its main products include iopofosine I-131, a radiopharmaceutical agent in development for the treatment of hematologic cancers such as Waldenstrom macroglobulinemia, as well as a pipeline of radioconjugates including CLR 125, an Auger-emitting PDC targeting solid tumors like triple-negative breast cancer, and CLR 225, an alpha-emitting radioconjugate in development for pancreatic cancer. The company also explores small molecule and oligonucleotide-conjugated drug candidates using its PDC platform. Cellectar Biosciences operates primarily in the oncology pharmaceutical sector with clinical and regulatory activities spanning the United States and Europe. The company was founded in 2003 and is headquartered in Madison, Wisconsin. Its recent corporate developments include receiving rare pediatric disease designation from the U.S. Food and Drug Administration for iopofosine I-131 for inoperable relapsed or refractory pediatric high-grade glioma and achieving eligibility to seek Conditional Marketing Authorization from the European Medicines Agency for iopofosine I-131 in post-BTK inhibitor refractory Waldenstrom macroglobulinemia, with plans for submission targeted in 2026. Cellectar initiated a Phase 1b clinical trial for CLR 125 in triple-negative breast cancer and completed IND-enabling studies for CLR 225. The company announced a strategic partnership with Evestia Clinical to provide CRO services for the CLR 125 trial. Additionally, it is actively exploring strategic alternatives, including potential partnerships, mergers, or acquisitions, to accelerate the development and commercialization of its radiopharmaceutical drug pipeline. Cellectar Biosciences focuses on delivering innovative cancer therapeutics through its novel PDC platform to treat a broad range of malignancies, aiming to improve therapeutic indices by targeting all tumor cells and cancer stem cells. The company’s recent strategic and operational initiatives underscore its commitment to advancing clinical trials, achieving regulatory milestones, and exploring collaborations to enhance shareholder value and bring impactful cancer treatments to market.
Company News
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer Therapy Transcript
Cellectar Biosciences, Inc. (CLRB) Q2 2026 Earnings Call Transcript
Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Analysts Set Cellectar Biosciences, Inc. (NASDAQ:CLRB) PT at $11.00
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting
Cellectar Biosciences, Inc. (CLRB) Q1 2026 Earnings Call Transcript
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026
Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know
What's Going With Cellectar Biosciences Stock On Wednesday?
Cellectar Biosciences Stock Rallies As Blood Cancer Data Impresses
Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia
Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC)
Cellectar Biosciences, Inc. (CLRB) Q4 2025 Earnings Call Transcript
Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates